Form 8-K - Current report:
SEC Accession No. 0001628280-23-021539
Filing Date
2023-06-08
Accepted
2023-06-08 16:40:13
Documents
12
Period of Report
2023-06-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20230608.htm   iXBRL 8-K 60953
  Complete submission text file 0001628280-23-021539.txt   203274

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20230608.xsd EX-101.SCH 1959
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20230608_lab.xml EX-101.LAB 24947
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20230608_pre.xml EX-101.PRE 13180
6 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20230608_htm.xml XML 11781
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 231002516
SIC: 2834 Pharmaceutical Preparations